The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Open accessAbstract
Target protein degradation (TPD) is a new avenue that is revolutionary for therapeutics because it redefines the principles of classical drug discovery, guided by event-based target activity rather than by occupancy-driven activity. Since the discovery of the first proteolysis-targeting chimera (PROTAC) in 2001, TPD represents a rapidly growing technology, with applications in both drug discovery and chemical biology. Over the past decade, many questions have been raised, some of which have been addressed, although there is still a long way to go. In this review, we discuss the challenges that the PROTAC strategy has recently addressed in drug design and discovery by highlighting recent results from the literature, and provide guidelines for medicinal chemists interested in the design of new PROTACs as successful therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Cited by
Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39
Liver-targeting chimeras as a potential modality for the treatment of liver diseases
Chen, C., Pan, Y., Yang, X., Li, H., Cai, X., He, S., Wang, Q., Yang, Y., Zheng, R., Li, H., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.044 · Cited by 25
Metadata
- Authors
- Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., & Voisin-Chiret, A. S.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2023-01
- Volume
- 28
- Issue
- 1
- Pages
- 103395
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W4304080843
- Cited by
- 162
- References
- 32
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. https://app.cochat.ai/papers/10.1016/j.drudis.2022.103395
- The paper
- Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., & Voisin-Chiret, A. S. (2023). PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2022.103395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.